All filters
Slidesets
Mathematical model of drug-target binding predicts optimal antibiotic treatment - P. Abel zur Wiesch
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015
Slidesets
TB and Diabetes Mellitus: Pharmacological Aspects of the Convergence of Two Epidemics - Rovina Ruslami, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015
Slidesets
Digitizing MTB Medicines: Using compounding methods to enable mobile capture of MTB medication adherence - S. Browne
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015
Slidesets
Prediction of drug partitioning into tubercular pulmonary lesions - C. Chen
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015
Slidesets
Drug Partitioning and Local Microenvironmental Conditions affect Bedaquiline, Clofazimine and Pyrazinamide Treatment Responses in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice - S. Irwin
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015
Slidesets
Quantitative modeling of time to positivity following dosing of bedaquiline and rifafour in patients with pulmonary tuberculosis infection - J.F. Marier
Presented at:
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2015
Slidesets
TDF Use Across the Age Spectrum: From Fetus to Adolescent - Anna Turkova, MD
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Debate: CD4 Assays Are No Longer Needed for Care of Children in Lowresource Countries - Ted Ruel, MD
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
CON ‐ standpoint - Diana Gibb, MD, MRCP, MSc
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Pediatric Treatment Cascade: What Do We Need to Reach “90‐90‐90” for Children - Elaine Abrams, MD
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Virologic Outcomes of Children Switched from Lopinavir/Ritonavir‐ to Efavirenz‐Based Antiretroviral Treatment: a retrospective cohort study - Kirsten Reichmuth
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Lopinavir ritonavir (1:1 ratio) in the presence of rifampicin is not inferior to lopinavir ritonavir (4:1 ratio) in the absence of rifampicin in HIV children. Interim analysis of an open label sequential non- randomized phar- Mark Cotton
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
The effect of systemic exposure to efavirenz, sex and age on the risk of virological non‐suppression in HIV‐infected African children - Andrzej Bienczak
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Durability of first‐line antiretroviral therapy (ART) in children in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) - Ruth Goodall
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Reasons for delayed ART initiation in children with HIV in South Africa - Chloe Teasdale
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Efavirenz‐based therapy may simplify antiretroviral LPV‐based therapy initiated in HIV‐1‐infected children before the age of 2 in West‐Africa: the MONOD trial ANRS 12206 - Valeriane Leroy
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Bridging Worlds: Perinatally‐Infected Youth and Transition to Adult Care - Caroline Foster, MBBS, MRCPCH
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Anxiety and depression in young people with perinatal HIV and their HIV negative siblings - Marthe Le Prevost
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Innovative Adherence Interventions for HIV‐Infected Youth - Rachel Vreeman, MD, MS
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Hepatitis B Treatment Response to TDF in 3TC‐experienced Perinatally HIVinfected Adolescents - Linda Aurpibul
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease and Liver Fibrosis among Perinatally HIV‐infected Asian Adolescents - Tavitiya Sudjaritruk
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Week 48 safety and efficacy of a rilpivirine (TMC278)‐based regimen in HIVinfected treatment‐naïve adolescents: PAINT Phase II trial - Patricia Flynn
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Second‐line ART treatment and resistance outcomes of Asian children - Annette Sohn, MD
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Overview lecture on Pros and Cons - Lynne Mofenson, MD
Presented at:
International Workshop on HIV & Pediatrics 2015